Dyadic International (DYAI) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$3.8M

Revenue (quarter)

$961,138.00

Revenue growth (year over year)

−0.57%

Gross profit (trailing twelve months)

$617,621.00

Gross margin

16.24%

Net income (trailing twelve months)

−$7.6M

Net income (quarter)

−$2.1M

Net income growth (year over year)

−18.40%

Net margin

−200.46%

Return on equity

—

EPS (trailing twelve months)

−$0.21

Book value per share

−$0.07

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

136.52%

Payout ratio

—

Dividend yield

—

Company profile

Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

• Is Dyadic International (DYAI) profitable?

  No. Dyadic International reported a net loss of $7.6M over the trailing twelve months.

• How much revenue does Dyadic International (DYAI) make?

  Dyadic International generated $3.8M in revenue over the trailing twelve months, down 0.57% year over year.

• How do I buy stock in Dyadic International (DYAI)?

  DYAI trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.